SCHEDULE: Peter Thiel's Entities Disclose 7.5% Stake in 180 Life Sciences
Schedule 13G Filing
Peter Thiel and affiliated entities have disclosed a beneficial ownership of 7.5% in 180 Life Sciences Corp., totaling 11,592,241 common shares.
Summary
- Peter Thiel, through various affiliated entities including FF Consumer Growth II, LP and FF Consumer Growth, LLC, beneficially owns 11,592,241 shares of 180 Life Sciences Corp. common stock.
- This aggregate ownership represents 7.5% of the company's outstanding common stock.
- FF Consumer Growth II, LP directly holds 8,935,990 shares, accounting for 5.8% of the class.
- FF Consumer Growth, LLC directly holds 2,656,251 shares, accounting for 1.7% of the class.
- The percentage of class is based on 154,032,084 shares of common stock outstanding as of August 4, 2025.
- All reporting persons, including Peter Thiel, hold shared voting and shared dispositive power over their respective beneficially owned shares.
- The reporting persons expressly disclaim status as a 'group' for the purposes of this Schedule 13G filing.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the company's performance or prospects. The sentiment is neutral.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
The disclosure of a significant stake by a prominent investor like Peter Thiel, known for his investments in technology and life sciences, can signal investor confidence or strategic interest in the biotechnology sector, particularly for companies like 180 Life Sciences Corp. operating in this space.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Group Status Disclaimer | The reporting persons, including Peter Thiel and his affiliated entities, expressly disclaim status as a 'group' for purposes of this Schedule 13G. | 08/04/2025 | This disclaimer clarifies that the reporting persons do not intend to act in concert to control or influence the issuer, which can be relevant for corporate governance and regulatory compliance. |
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes by influential investors, which can influence market perception and potentially signal confidence in the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 08/04/2025 | Date of event which requires the filing of this statement, and the date for which outstanding shares were reported. |
| 08/05/2025 | Date of Issuer's Current Report on Form 8-K, which reported the number of outstanding common shares. |
| 08/11/2025 | Date the Schedule 13G and Joint Filing Agreement were executed. |
Keywords
180 Life Sciences Corp., Peter Thiel, Founders Fund, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Biotechnology, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.